Canine Adenovirus 1: Infectious Canine Hepatitis Reference

Overview and Taxonomy of Canine Adenovirus 1 (Infectious Canine Hepatitis)

Taxonomic Classification and Phylogenetic Position

Canine adenovirus type 1 (CAdV-1) is a non-enveloped, linear double-stranded DNA virus belonging to the family Adenoviridae, genus Mastadenovirus [2, 24]. This classification places it within a broad group of mammalian adenoviruses that share structural and genomic organizational features. The Mastadenovirus genus encompasses numerous pathogens of veterinary and medical significance, including human adenoviruses, with which CAdV-1 shares considerable homology in core structural proteins and replication machinery [13]. At the species level, CAdV-1 is formally designated as Canine mastadenovirus A, a taxon that also includes canine adenovirus type 2 (CAdV-2), though these two serotypes are now recognized as distinct viral entities with divergent pathogenic profiles and tissue tropisms [2, 24].

Historically, the differentiation between CAdV-1 and CAdV-2 remained ambiguous for decades, with early investigators considering the Toronto A26/61 strain, later identified as CAdV-2, merely an attenuated variant of the classical infectious canine hepatitis (ICH) virus [30]. Definitive serological characterization using hemagglutination-inhibition (HI), serum-virus neutralization (SN), and complement-fixation (CF) tests ultimately resolved this confusion, establishing that the two viruses constitute distinct homogeneous antigenic groups [30]. This antigenic distinction is further supported by genomic analyses: CAdV-1 possesses a genome of approximately 30,535 base pairs, as exemplified by the fox-derived F1301 strain, which demonstrates high homology with other CAdV-1 isolates but clear divergence from CAdV-2 strains [33]. The phylogenetic relationships among global CAdV-1 isolates reveal complex patterns of regional evolution, with strains from the Indian subcontinent, Europe, Asia, and Australasia forming distinct clusters that reflect both historical viral dissemination and contemporary ecological pressures [2, 9, 15].

Molecular and Structural Characteristics

The CAdV-1 virion exhibits the classic icosahedral symmetry characteristic of all adenoviruses, with a diameter of approximately 70–90 nm and a capsid composed primarily of hexon, penton, and fiber proteins [24, 35]. The hexon protein serves as the major capsid component and contains type-specific antigenic determinants that form the basis for serological differentiation between CAdV-1 and CAdV-2 [24]. Hemagglutination assays utilizing guinea pig erythrocytes have long been employed for preliminary identification, with CAdV-1 strains demonstrating consistent agglutinating activity that distinguishes them from CAdV-2 [35]. The fiber protein, responsible for primary attachment to host cell receptors, exhibits significant sequence variability between serotypes and even among CAdV-1 field strains, with the receptor-binding knob domain undergoing evolutionary selection pressures that may influence host range and tissue tropism [24, 34].

The viral genome is organized into early (E) and late (L) transcription units, with the E3 region being of particular diagnostic and epidemiological importance. The E3 gene encodes proteins involved in immune evasion and host cell modulation, and sequence analysis of this region has become a standard tool for molecular characterization and phylogenetic studies [2, 9, 18, 26]. Notably, the E3 protein has been shown to harbor amino acid substitutions, such as Asn127Asp, His129Arg, Trp148Ser, Leu201Pro, Thr206Met, and Gly215Glu, that distinguish field isolates from vaccine strains and may correlate with regional patterns of viral evolution [9, 15]. The W126S substitution identified in an Indian CAdV-1 isolate from a Rajapalayam dog further illustrates the ongoing genetic diversification within this serotype [2]. Selection pressure analyses indicate that the CAdV-1 genome is subject predominantly to purifying selection, although certain codons within the hexon and fiber genes experience weak or episodic positive selection, likely reflecting host immune-driven adaptation [9].

Differentiation from Canine Adenovirus Type 2

A precise understanding of the taxonomic and biological distinctions between CAdV-1 and CAdV-2 is essential for accurate diagnosis, epidemiological surveillance, and vaccine development. While both serotypes share a common ancestor and exhibit similar morphological features, including identical capsid architecture and indistinguishable cytopathic effects in cell culture, their pathogenic profiles diverge markedly [24]. CAdV-1 is the etiological agent of infectious canine hepatitis, a systemic disease characterized by necrohemorrhagic hepatitis, vasculitis, and multisystemic hemorrhage, with a particular tropism for hepatic parenchyma, vascular endothelium, and renal epithelium [1, 5, 8, 11, 15, 22, 24, 37]. In contrast, CAdV-2 primarily infects the respiratory epithelium, causing infectious tracheobronchitis (kennel cough) and, in severe cases, bronchopneumonia; it lacks the systemic endothelial tropism that defines CAdV-1 pathogenicity [20, 21, 23, 24, 29, 30].

This divergence in tissue tropism is reflected in the differential expression of viral genes and receptor utilization. The CAdV-2 fiber protein exhibits sequence variation in its head domain that alters receptor specificity, restricting the virus to respiratory epithelial cells and preventing the widespread endothelial infection characteristic of CAdV-1 [24, 34]. Furthermore, CAdV-2 strains such as the Toronto A26/61 isolate and the Chinese CAV-HN45 strain have demonstrated the capacity to infect cells of multiple mammalian species, including human cervical cancer cell lines, highlighting their potential as gene therapy vectors and raising questions about the zoonotic implications of adenoviral cross-species transmission [4, 30, 32]. Despite these differences, the two serotypes share sufficient antigenic homology that vaccination with modified-live CAdV-2 provides robust cross-protection against CAdV-1 challenge, a phenomenon exploited since the early 1980s to circumvent the adverse ocular reactions, notably corneal edema (“blue eye”), associated with CAdV-1 vaccines [10, 24, 30].

Host Range and Global Distribution

CAdV-1 exhibits a remarkably broad host range among carnivores, extending well beyond domestic dogs (Canis lupus familiaris) to encompass a diverse array of wild canids, ursids, and mustelids. Fatal ICH has been documented in captive Indian wolves (Canis lupus pallipes), dhole pups (Cuon alpinus), maned wolves (Chrysocyon brachyurus), and free-ranging gray wolves (Canis lupus) across multiple continents [1, 5, 8, 14, 27, 28]. The virus has also emerged as a significant conservation threat for endangered ursid populations, with confirmed mortality in European brown bears (Ursus arctos arctos) in the Cantabrian Mountains of Spain and a free-ranging brown bear cub (Ursus arctos horribilis) in Alaska [7, 14, 16]. Retrospective analysis of brown bear carcasses in Spain identified CAdV-1 as the cause of death in multiple individuals, with characteristic hepatic intranuclear inclusion bodies and immunohistochemical labeling of viral antigen in hepatocytes and Kupffer cells [16]. The detection of CAdV-1 DNA in 14% of free-ranging wolves in Asturias, with prevalence concentrated in juveniles under two years of age, supports the hypothesis that wolves serve as both reservoirs and sentinels for viral circulation in ecosystems shared with endangered sympatric carnivores [14].

Red foxes (Vulpes vulpes) have been identified as particularly important reservoirs, with seroprevalence rates reaching 64.4% in the United Kingdom and molecular detection rates of 22% in kidney samples from foxes in the UK, Italy, and Germany [18, 25]. Critically, many of these foxes exhibited inapparent infections, viral DNA was present in liver, kidney, spleen, brain, lung, and urine without associated histopathological lesions, indicating that red foxes can shed CAdV-1 into the environment over prolonged periods without clinical signs [18, 25]. This subclinical carrier state represents a major mechanism for viral maintenance and dissemination, particularly in regions where domestic dog vaccination is incomplete or where wildlife-livestock interfaces facilitate cross-species transmission. The isolation of CAdV-2 from wild raccoon dogs (Nyctereutes procyonoides) in Korea, with high genetic similarity to the vaccine strain Toronto A26/61, further underscores the potential for vaccine-derived viruses to establish reservoirs in wildlife populations [32].

CAdV-1 has been recognized as a globally distributed pathogen by the World Organisation for Animal Health (WOAH, founded as OIE), reflecting its significance as a transboundary disease with implications for both domestic animal health and wildlife conservation. Epidemiological surveys across Europe, Asia, and North America have confirmed the continued circulation of CAdV-1 in both vaccinated and unvaccinated dog populations, with seroprevalence rates varying widely by region and vaccination history [12, 17, 19, 26, 31, 36]. In a comprehensive multi-pathogen survey of 2,492 dogs across 22 Chinese provinces conducted between 2018 and 2024, CAdV-1 was detected at rates comparable to other core vaccine-preventable pathogens, and serological protective rates in vaccinated dogs reached 84.4% [12]. Outbreaks have been reported in animal shelters and breeding kennels in Italy, Portugal, India, and Turkey, often in association with other viral pathogens such as canine distemper virus, canine parvovirus, and canine coronavirus [9, 11, 12, 26, 31, 37]. The re-emergence of ICH in regions with historically high vaccination coverage, attributed to gaps in herd immunity, importation of unvaccinated animals from endemic areas, and waning vaccine-induced immunity, has prompted renewed attention to CAdV-1 as a re-emerging infectious disease [3, 6, 31].

Molecular Pathogenesis of Canine Adenovirus 1

The molecular pathogenesis of Canine Adenovirus 1 (CAdV-1), the aetiological agent of infectious canine hepatitis (ICH), represents a complex, multi-faceted interplay between viral replication strategies, host cellular machinery subversion, and a profoundly dysregulated immune response. As a member of the genus Mastadenovirus within the family Adenoviridae, CAdV-1 is a non-enveloped, linear double-stranded DNA virus with a genome of approximately 30.5 kb [2, 33]. Its pathogenesis is not merely a consequence of lytic hepatocyte destruction; rather, it is a systemic vascular disease driven by the virus's unique tropism for endothelial cells, Kupffer cells, and hepatocytes, culminating in a characteristic necrohaemorrhagic hepatitis, coagulopathy, and multi-organ failure [1, 8]. The World Organisation for Animal Health (WOAH) classifies ICH as a significant infectious disease of canids, and recent molecular studies have dramatically refined our understanding of the precise mechanisms of cellular injury, immune evasion, and systemic dissemination.

Molecular Architecture and Genomic Determinants of Pathogenicity

The CAdV-1 virion is an icosahedral particle composed of three major capsid proteins: hexon, penton base, and fiber. The hexon protein is the primary target for virus-neutralizing antibodies and contains hypervariable regions that determine serotype specificity and are under significant immune selection pressure [24, 34]. The fiber protein, a homotrimer projecting from the penton base, is the primary determinant of viral tropism. It mediates the initial high-affinity attachment to the host cell receptor, the coxsackievirus and adenovirus receptor (CAR) on canine cells. The fiber knob domain exhibits distinct structural features compared to CAdV-2, which correlates with the differing tissue tropisms of the two serotypes; CAdV-1 fiber is optimized for binding to receptors on hepatocytes and endothelial cells, whereas CAdV-2 fiber confers a tropism for respiratory epithelium [24, 30]. The penton base contains an Arg-Gly-Asp (RGD) motif that interacts with cellular integrins (αvβ3 and αvβ5), triggering virus internalization via clathrin-mediated endocytosis. Upon endosomal escape, the viral DNA traffics to the nucleus, where the early transcription program begins.

The CAdV-1 genome encodes several early (E) regions, E1A, E1B, E2, E3, and E4, that orchestrate the molecular hijacking of the host cell. The E3 region is of particular interest in pathogenesis, as it is not required for viral replication in vitro but is critical for immune evasion in vivo. E3 proteins, including the E3 gp19K homologue, function to retain major histocompatibility complex class I (MHC-I) molecules in the endoplasmic reticulum, thereby inhibiting the presentation of viral peptides to cytotoxic T lymphocytes (CD8+ T cells) [9]. Recent genomic analyses from field isolates in Northeast India and a fatal case in a Rajapalayam dog have identified notable mutations in the E3 protein, including substitutions Asn127Asp, His129Arg, Trp148Ser (W126S in some nomenclature), Leu201Pro, Thr206Met, and Gly215Glu [2, 9]. The Trp148Ser (W126S) mutation, first identified in a UK fox isolate, is located in a region of the E3 protein that may influence its interaction with MHC-I, potentially altering immune evasion capacity and contributing to viral fitness in different hosts [2]. The E1A region is the first to be expressed and functions as a potent transactivator of both viral and cellular genes, driving the infected cell into S-phase to create an optimal environment for viral DNA replication.

Cellular Entry, Replication Cycle, and Cytopathic Effect

After binding to CAR and integrins, the internalized virion undergoes a stepwise disassembly within the endosome. The acidic pH of the endosome triggers conformational changes in the capsid proteins, leading to endosomal membrane disruption and release of the partially uncoated virion into the cytoplasm. The viral DNA, along with the terminal protein, is then transported to the nuclear pore complex, where it is imported into the nucleoplasm. Within the nucleus, the viral genome is transcribed by host RNA polymerase II in a tightly regulated temporal cascade.

The replication cycle of CAdV-1 in Madin-Darby canine kidney (MDCK) cells is well-characterized, with peak titers (approx. 10⁷.⁵ TCID₅₀/mL) achieved approximately 4 days post-inoculation [35]. The virus induces a profound cytopathic effect (CPE) characterized by cell rounding, detachment, and the formation of large, basophilic or eosinophilic intranuclear inclusion bodies. These inclusions are Cowdry type A inclusions and represent paracrystalline arrays of progeny virions and viral proteins within the nucleus [1, 5, 8, 15]. The inclusions are a pathognomonic feature of CAdV-1 infection in hepatocytes, Kupffer cells, and endothelial cells [1, 11]. The E2 region encodes the viral DNA polymerase and other replication factors. The genome replication proceeds via a protein-primed mechanism involving the terminal protein (TP) covalently attached to the 5' ends of the linear DNA. Late gene expression (primarily the capsid proteins, hexon, penton, fiber) is dependent on the onset of DNA replication and is driven by the major late promoter. The assembly of progeny virions occurs in the nucleus, and cell lysis ultimately releases thousands of infectious particles.

Vascular Endotheliotropism and the Pathogenesis of Haemorrhagic Diathesis

The cardinal feature of CAdV-1 pathogenesis is its tropism for vascular endothelium. This is not a bystander effect of hepatitis but a direct, virus-induced injury. The virus infects endothelial cells throughout the body, leading to widespread vasculitis and increased vascular permeability. This is evident in the gross necropsy finding of petechial and ecchymotic haemorrhages on the serosal surfaces of the liver, spleen, kidneys, lungs, and gastrointestinal tract [1, 5, 8]. The molecular basis for this endothelial injury involves the activation of the coagulation cascade and the subsequent disseminated intravascular coagulation (DIC). Thrombocytopenia, prolonged coagulation times (prothrombin time and activated partial thromboplastin time), and depletion of clotting factors are hallmarks of severe ICH [3, 5, 11]. The virus induces a consumptive coagulopathy, and the resulting microthrombi in small vessels contribute to ischaemic necrosis in the liver and other organs.

The hepatic lesion begins with infection of Kupffer cells, the resident hepatic macrophages, followed by spread to adjacent hepatocytes [1]. Immunohistochemical studies have consistently demonstrated CAdV-1 antigen within both hepatocytes and Kupffer cells [1, 16]. The virus induces necrohaemorrhagic hepatitis, characterised by multifocal to coalescing areas of lytic necrosis, haemorrhage into the parenchyma, and a minimal to absent inflammatory infiltrate in the acute phase [15, 40]. The lack of a robust early inflammatory response is typical of adenovirus infections, as the virus actively suppresses host innate immunity. The massive hepatocyte destruction leads to a profound release of liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP]) into the circulation and a dramatic decrease in hepatic synthetic function, resulting in severe hypoalbuminaemia, which manifests clinically as peripheral oedema (particularly of the head and limbs) and ascites [3, 5, 8, 11]. The hyperbilirubinaemia and icterus reflect the inability of the damaged liver to process bilirubin [5, 8].

Molecular Basis of Immune Evasion and PANoptosis

Recent groundbreaking research has elucidated a novel and devastating mechanism of cellular destruction in CAdV-1 infection: PANoptosis [39]. PANoptosis is a unique, highly inflammatory form of programmed cell death that integrates key features of pyroptosis, apoptosis, and necroptosis, and is driven by the activation of inflammasomes. Li et al. (2026) demonstrated that CAdV-1 infection induces PANoptosis in canine splenocytes (T cells and B cells) via the activation of the absent in melanoma 2 (AIM2) inflammasome [39]. The viral double-stranded DNA (dsDNA) is sensed by AIM2, a cytosolic pattern recognition receptor. This triggers the assembly of the AIM2 inflammasome complex, leading to the cleavage of pro-caspase-1 into active caspase-1. Active caspase-1 then cleaves pro-interleukin-1β (pro-IL-1β) and pro-IL-18 into their mature, secreted forms, driving a potent inflammatory response. Simultaneously, this pathway can induce gasdermin D (GSDMD) cleavage, leading to pyroptotic pore formation in the cell membrane and lytic cell death. The study found that while AIM2 expression was not significantly altered in the primary target organs (liver and kidney), it was markedly upregulated in immune organs, specifically the spleen, tonsils, and lymph nodes, where it correlated with PANoptosis of lymphocytes [39]. This provides a molecular explanation for the profound lymphopaenia and splenic pathology (fibrinous-necrotizing splenitis) observed in ICH [8, 11]. The depletion of lymphocytes, which are key effectors of the adaptive immune response, further cripples the host's ability to control viral replication.

In addition to PANoptosis, the virus employs multiple immune evasion tactics. The E3 protein's inhibition of MHC-I presentation, as discussed, protects infected cells from CD8+ T cell-mediated killing [9]. Furthermore, the virus encodes proteins that interfere with the interferon (IFN) response. The early protein E1A suppresses the transcription of IFN-stimulated genes (ISGs), while other viral proteins can inhibit the activation of protein kinase R (PKR), a key antiviral effector that halts protein synthesis. Proteomic and transcriptomic analyses of CAdV-1-infected MDCK cells have revealed the involvement of the PI3K-AKT, Wnt, and Hepatitis C pathways, highlighting the complex reprogramming of cellular signalling by the virus to favour replication and suppress apoptosis [33].

Neurotropism and the "Blue Eye" Phenomenon

CAdV-1 is also capable of infecting the central nervous system (CNS) and the eye, leading to distinct clinical manifestations. Neurological signs, including ataxia, circling, seizures, and obtundation, are uncommon but well-documented, particularly in young, unvaccinated animals [8, 22, 26, 38]. The molecular basis of CNS invasion is likely haematogenous, as the virus crosses the blood-brain barrier via infected endothelial cells of the cerebral microvasculature. Histopathological findings include a non-suppurative meningoencephalitis and, critically, vasculitis of the brain with intranuclear inclusion bodies in endothelial cells [22]. This neurotropism has been confirmed by immunohistochemistry demonstrating CAdV-1 antigen in brain tissue [22].

The "blue eye" phenomenon is a classic but transient complication of ICH, observed in convalescent animals or following vaccination with live-attenuated CAdV-1 vaccines [10, 24, 36]. It is not a direct result of viral replication in the cornea but rather an immune-complex-mediated reaction. As the host mounts an antibody response to the viral antigens, circulating CAdV-1–antibody complexes deposit in the corneal endothelium, activating the complement cascade and leading to a neutrophilic infiltration that causes corneal oedema, giving it a characteristic blue or cloudy appearance [24, 40]. This phenomenon is now rarely seen with the widespread use of CAdV-2-based vaccines, which lack the CAdV-1-specific antigenic determinants that trigger this reaction but still confer cross-protective immunity [10].

Molecular Determinants of Host Range and Interspecies Transmission

CAdV-1 exhibits a broad host range within the order Carnivora, causing fatal disease not only in domestic dogs but also in wild canids (wolves, foxes, dholes, maned wolves), ursids (brown bears, black bears), and mustelids [1, 5, 7, 8, 14, 16, 18]. The molecular basis of this broad host range is not fully understood, but it is related to the conserved nature of the CAR receptor across mammalian species. The ability of CAdV-1 to infect and cause disease in European brown bears (Ursus arctos arctos) is a significant conservation concern, with wolves acting as potential wildlife reservoirs and sentinels for viral spillover into sympatric bear populations [14, 16]. Whole-genome sequencing of CAdV-1 isolates from a wolf in southern Italy revealed a high degree of genomic conservation, with the virus showing close similarity to European canine and fox isolates [27]. This suggests a lack of strict host adaptation at the genomic level, enabling the virus to jump species barriers with relative ease. The molecular characterization of the E3 gene in isolates from red foxes has identified both synonymous and non-synonymous mutations, suggesting ongoing adaptation within wild reservoirs [18, 25]. The detection of CAdV-1 DNA in the urine of asymptomatically infected red foxes is a critical epidemiological finding, indicating a mechanism for environmental contamination and transmission to naive hosts [25].

Subversion of Hepatic Metabolism and Oxidative Stress

The acute phase of CAdV-1 infection induces a state of profound metabolic dysregulation and oxidative stress in the liver. As the virus hijacks the hepatocyte's biosynthetic machinery for genome replication and virion assembly, it triggers a surge in reactive oxygen species (ROS) production. Concurrently, the host's antioxidant defences are overwhelmed. A clinical study of a CAdV-1-infected dog documented a marked increase in serum oxidant levels and a corresponding decrease in antioxidant capacity [15]. This oxidative stress is a direct contributor to the hepatocyte necrosis observed histopathologically. The molecular pathway likely involves the activation of NADPH oxidases and mitochondrial dysfunction, leading to lipid peroxidation and DNA damage within the infected cells. The resulting hyperglycaemia, often noted in clinical cases, may be a consequence of both the acute stress response and impaired hepatic gluconeogenesis due to widespread necrosis [15].

In summary, the molecular pathogenesis of CAdV-1 is a sophisticated strategy of host cell manipulation, immune evasion, and tissue destruction. It begins with receptor-mediated entry into hepatocytes and endothelial cells, proceeds through a lytic replication cycle that culminates in the formation of pathognomonic intranuclear inclusion bodies, and ultimately leads to systemic disease via a combination of direct viral cytopathology, severe oxidative stress, complementary-mediated immunopathology (blue eye), and the newly discovered mechanism of AIM2-driven PANoptosis of lymphocytes. The virus's ability to induce a consumptive coagulopathy and suppress the adaptive immune response makes it a uniquely formidable pathogen, capable of causing rapid mortality in naive populations across a wide range of carnivorous hosts.

Clinical Manifestations and Gross Pathology of Infectious Canine Hepatitis

The clinical trajectory and gross pathological alterations induced by Canine Adenovirus Type 1 (CAdV-1) represent a profound and often rapidly fatal systemic vasculotropic disease. The virus exhibits a primary tropism for endothelial cells, hepatic parenchyma, and renal tubular epithelium, leading to a constellation of clinical signs that are frequently age-dependent and influenced by the immune status of the host. The clinical manifestations span a spectrum from peracute death with no premonitory signs to a protracted, chronic illness characterized by intermittent fever and corneal edema, the pathognomonic “blue eye.” The gross pathology, in turn, reflects the severe necrotizing hepatitis, widespread hemorrhagic diathesis, and serosal effusions that define the acute form of infectious canine hepatitis (ICH). These findings have been consistently documented across canine populations and wild canids, including Indian wolves (Canis lupus pallipes) [1], dholes (Cuon alpinus) [5], maned wolves (Chrysocyon brachyurus) [8], and even non-canid hosts such as European brown bears (Ursus arctos arctos) [16, 40], underscoring the cross-species pathogenicity of this highly conserved virus.

Clinical Manifestations

The incubation period for naturally acquired CAdV-1 infection is typically 4 to 9 days, after which the clinical syndrome can manifest in one of several forms: peracute, acute (typical), subacute, or chronic. The peracute form, most commonly observed in very young or immunologically naïve neonates, is characterized by sudden death with minimal to no antecedent clinical signs. In a reported outbreak among captive Indian wolves, the first affected animal exhibited only lethargy, anorexia, and pyrexia before succumbing suddenly; the remaining three animals in the pack followed a similarly rapid course within 24 hours, displaying nearly identical symptoms [1]. This pattern of rapid, synchronized mortality in a cohort suggests high viral virulence and a lack of pre-existing maternal antibodies.

Acute Disease Presentation: The classic acute syndrome is dominated by a biphasic fever (often reaching 40.0–41.0°C), profound depression, and complete anorexia. Affected animals are typically dehydrated and may exhibit a painful abdomen upon palpation, a reflection of hepatic capsule distension and peritonitis [3, 38]. Vomiting and diarrhea, frequently hemorrhagic, are common gastrointestinal signs, leading to rapid fluid and electrolyte losses [37]. Polydipsia and polyuria may precede these signs by 24–48 hours. A critical and life-threatening feature is the development of a bleeding diathesis. Clinically, this manifests as prolonged bleeding from venipuncture sites, petechiation and ecchymoses on visible mucous membranes, epistaxis, and melena [3, 5]. This coagulopathy stems from a combination of reduced hepatic synthesis of clotting factors (particularly factors II, VII, IX, and X) and a consumptive thrombocytopenia secondary to widespread endothelial damage and disseminated intravascular coagulation (DIC). In a 4-month-old mixed-breed puppy imported from Bulgaria, clinicians observed a marked bleeding tendency at venous puncture sites, which, combined with severe hypoalbuminemia leading to peripheral edema of the head and limbs, necessitated aggressive treatment with whole blood and fresh frozen plasma transfusions [3].

Icterus and Hepatic Encephalopathy: As the disease progresses, icterus becomes clinically evident, particularly on the sclera, oral mucosa, and non-pigmented skin. This jaundice is a direct consequence of massive hepatocellular necrosis leading to an inability to conjugate and excrete bilirubin. Serum biochemistry in such cases reveals marked elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin, coupled with profound hypoalbuminemia and hypoproteinemia [5, 11, 15]. In the most severe cases, hepatic encephalopathy may ensue, characterized by central nervous system depression, head pressing, circling, and ultimately coma. Interestingly, neurological signs can also arise from a primary viral vasculitis within the central nervous system, independent of liver failure. A case report of a 5-week-old puppy presenting with acute-onset circling, ataxia, vocalization, and obtundation demonstrated that CAdV-1 can cause significant neurologic disease even without fulminant hepatic failure; histopathology revealed a severe vasculitis in the brain with characteristic intranuclear inclusion bodies in endothelial cells [22]. This dual mechanism for neurological involvement, metabolic (hepatic encephalopathy) versus direct viral (vasculitis and endothelial infection), complicates the clinical picture.

Ocular Manifestations (Blue Eye): A hallmark and often the only clinical sign in the chronic or convalescent phase is unilateral or bilateral corneal edema, commonly termed “blue eye.” This phenomenon results from an immune-complex deposition (type III hypersensitivity) within the corneal endothelium, leading to endothelial cell damage and disruption of the normal fluid-pumping mechanism of the cornea. The cornea becomes edematous and takes on a characteristic translucent blue-white opacity. Importantly, this sign can appear 1–3 weeks after the initial febrile episode, even in animals that are otherwise clinically recovering. It is particularly well-documented in dogs receiving modified-live CAdV-1 vaccines and was historically a significant adverse event; notably, this has been largely circumvented by the use of CAdV-2 vaccines, which cross-protect against CAdV-1 but do not induce corneal edema [10]. Histologically, the “blue eye” is characterized by corneal epithelial degenerative changes and edema without an inflammatory cell infiltrate [40].

Subclinical and Carrier State: A substantial proportion of infections, particularly in older or partially immune animals, are subclinical. In a serosurvey of free-ranging red foxes (Vulpes vulpes) in the United Kingdom, 64.4% of animals were seropositive for CAdV, yet many showed no gross or microscopic lesions at necropsy, and viral DNA was detected in 18.8% of clinically healthy animals [25]. Similarly, CAdV-1 DNA was detected in the urine of three red foxes with inapparent infections, underscoring the potential for asymptomatic shedders to maintain viral circulation within a population [25]. These subclinically infected animals play a pivotal role in the epidemiology of ICH, functioning as silent reservoirs that contaminate the environment through urine and feces. The World Organisation for Animal Health (WOAH) has long recognized this carrier state as a critical obstacle to disease eradication in wild canid populations.

Gross Pathology

The gross pathological changes observed at necropsy are amongst the most dramatic in veterinary medicine and are highly characteristic of acute CAdV-1 infection. The hallmark triad includes (a) a mottled, friable, and frequently icteric liver, (b) widespread petechial and ecchymotic hemorrhages on serosal surfaces, and (c) significant serous effusions within body cavities.

Hepatic Lesions: The liver is the central target organ. It is invariably enlarged (hepatomegaly), often to two or three times its normal size, with rounded, blunted edges [1, 5]. The parenchyma is exceptionally friable, to the point of fragmentation upon handling, and exhibits a striking mottled appearance: alternating areas of dark red (hemorrhagic necrosis) and pale tan to yellow (ischemic necrosis and fatty change) are scattered throughout the capsule and cut surface [5, 37]. In jaundiced animals, the entire organ takes on a uniform, deeply bilious yellowish-green hue [5]. The gallbladder wall is frequently thickened and edematous, a finding that can be quite pronounced, although this lesion is more classically associated with CAdV-2 infections causing respiratory disease [40]. The severe friability of the liver is a direct result of confluent hepatocellular necrosis, which destroys the structural integrity of the hepatic cords.

Hemorrhagic Diathesis: The widespread endothelial damage caused by CAdV-1 results in a systemic hemorrhagic syndrome that is readily apparent on gross inspection. Punctate to coalescing petechial hemorrhages are commonly observed on the serosal surfaces of the liver, spleen, kidneys, lungs, skeletal muscles, and the gastrointestinal tract (particularly the gastric and intestinal mucosa) [1, 5, 8, 37]. In severe cases, these hemorrhages can become ecchymotic, forming large, irregular patches of extravasated blood. The kidneys frequently show petechiae scattered across the cortical surface, resembling a “flea-bitten” kidney, which is a classic gross description. In maned wolves, subchondral hemorrhages have been reported in the articular cartilage of the femoral-tibial-patellar and tarsal joints, a less common but notable finding [8]. The presence of hemorrhagic fluid within the thoracic and abdominal cavities (hemothorax, hemoperitoneum) is a frequent finding in peracute cases, reflecting the severity of the coagulopathy and vascular leakage [16].

Lymphoid and Splenic Changes: The spleen is typically enlarged (splenomegaly) and congested, appearing dark red to black on cut surface [8, 15]. The lymphoid tissues, including the tonsils and lymph nodes (particularly the hepatic, renal, and mesenteric nodes), are often swollen, edematous, and hemorrhagic [8]. This reflects the profound lymphotropism of the virus; recent research has demonstrated that CAdV-1 induces PANoptosis, a form of programmed cell death involving pyroptosis, apoptosis, and necroptosis, in canine splenocytes via activation of the AIM2 inflammasome pathway, leading to significant depletion of T and B cells [39]. This lymphoid destruction contributes to the leukopenia and thrombocytopenia observed clinically and increases the host's susceptibility to secondary infections.

Subcutaneous and Serosal Effusions: Generalized edema is a prominent gross feature in many fatal cases. Gelatinous, straw-colored to hemorrhagic fluid accumulates in the subcutaneous tissues, particularly in the submandibular region, the inguinal area, and the dependent portions of the limbs [5, 37]. This subcutaneous edema is a direct consequence of severe hypoalbuminemia secondary to hepatic synthetic failure, combined with increased vascular permeability due to endothelial injury. In the puppy described by Duarte et al. (2018), generalized gelatinous subcutaneous edema was one of the most striking findings, contributing to a "waterlogged" appearance of the carcass [37]. Serous effusions within the thoracic cavity (hydrothorax), pericardial sac (hydropericardium), and abdominal cavity (ascites) are similarly common, further compounding the hypovolemic shock often seen in terminal stages [16].

Other Organ Findings: The lungs are frequently congested, edematous, and may exhibit areas of atelectasis or emphysema [15]. The gastrointestinal tract shows a diffuse, hemorrhagic enteritis, with the lumen often containing dark, tarry blood (melena) [15, 37]. The brain can appear grossly normal even in cases with significant histological vasculitis, though in some instances, meningeal congestion may be noted. The thymus, particularly in young animals, is often atrophied and hemorrhagic, reflecting the profound lymphoid depletion induced by the virus.

In summary, the clinical manifestations of ICH span from peracute death to a protracted, multisystemic illness dominated by fever, coagulopathy, hepatic failure, and neurological signs. The gross pathological correlate is a constellation of hemorrhagic necrosis of the liver, generalized petechiation, lymphadenopathy, and serosal edema, a tableau that, when encountered by the pathologist, is virtually pathognomonic for acute CAdV-1 infection. The recognition of these signs, particularly in unvaccinated juvenile animals and sympatric wild canids, is critical for early intervention and the implementation of containment measures.

Diagnostic Approaches for Canine Adenovirus 1 Infection

The accurate and timely diagnosis of Canine Adenovirus 1 (CAdV-1) infection, the etiological agent of Infectious Canine Hepatitis (ICH), is paramount for effective clinical management, outbreak control, and epidemiological surveillance. Given the virus's ability to cause rapid, fatal disease, particularly in unvaccinated juvenile canids and vulnerable wildlife populations, diagnostic approaches must be both sensitive and specific. The diagnostic landscape for CAdV-1 has evolved considerably, moving from classical pathological and virological methods to a sophisticated array of molecular, serological, and immunohistochemical techniques. This section provides an exhaustive analysis of these diagnostic modalities, their underlying principles, applications, and interpretative nuances, drawing exclusively from the provided literature.

Gross and Histopathological Examination

The cornerstone of initial CAdV-1 diagnosis, particularly in postmortem investigations, remains the meticulous evaluation of gross and histopathological lesions. Necropsy findings in acute ICH are often pathognomonic, providing a strong presumptive diagnosis. A consistent observation across multiple studies is the presence of a soft, enlarged, and discolored liver with rounded borders, often described as friable, hemorrhagic, and severely icteric [1, 5, 37]. Widespread petechial and ecchymotic hemorrhages are a hallmark, frequently observed on the liver, spleen, kidneys, lungs, skeletal muscles, and gastrointestinal mucosa [1, 5, 8]. Subcutaneous edema, particularly in the submandibular, inguinal, and hindlimb regions, is another common finding, often associated with severe hypoalbuminemia [5, 8, 37]. The classic "bloody bacon" appearance of the liver, while not always present, is highly suggestive. Gallbladder edema, characterized by a thickened, edematous wall, is a frequently cited lesion, though it is important to note that immunohistochemical studies have shown that this lesion is more consistently associated with canine distemper virus (CDV) antigen than with CAdV-1 [40]. Other gross changes include splenomegaly, lymphadenomegaly, and a general serosanguinous effusion in body cavities [1, 8, 15].

Histopathologically, the diagnosis hinges on the identification of characteristic intranuclear inclusion bodies (INIBs). These are large, basophilic or eosinophilic structures that fill and expand the nucleus of infected cells, most notably hepatocytes and Kupffer cells in the liver [1, 2, 5, 8]. The presence of these INIBs is considered a hallmark of CAdV-1 infection. The hepatic parenchyma typically exhibits severe necrohemorrhagic hepatitis, with areas of hepatocellular degeneration, necrosis, and severe vascular congestion [1, 15]. The virus's tropism for vascular endothelium is a key pathogenic feature, leading to widespread vasculitis and endothelial damage. This is reflected histologically by engorged and dilated sinusoids and hemorrhages in multiple organs, including the lungs, kidneys, spleen, heart, and intestines [1]. In the kidneys, interstitial nephritis with INIBs in glomerular endothelial cells and tubular epithelium can be observed [8, 15]. Neurological involvement, though less common, is characterized by non-suppurative meningoencephalitis and vasculitis in the brain, with INIBs found in endothelial cells [8, 22]. While histopathology provides a rapid and cost-effective presumptive diagnosis, its sensitivity can be compromised by autolysis, as highlighted in cases where body freezing hampered definitive histopathological interpretation [37]. Therefore, confirmatory tests are essential.

Molecular Diagnostics: Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR)

Molecular techniques, particularly polymerase chain reaction (PCR) and its quantitative variant (qPCR), have become the gold standard for definitive CAdV-1 diagnosis due to their unparalleled sensitivity, specificity, and rapid turnaround time. These methods detect the viral DNA directly, allowing for confirmation even in cases where histopathology is inconclusive or when only non-invasive samples are available.

Conventional and Nested PCR: Standard PCR assays, often targeting the E3 gene, are widely used for the detection of CAdV-1 DNA in a variety of clinical and postmortem samples. This approach has been successfully employed to confirm infection in liver, kidney, spleen, lung, and brain tissues from domestic dogs and a wide range of wild canids, including Indian wolves, dholes, maned wolves, and red foxes [1, 2, 5, 18, 25]. The E3 gene is a common target because it encodes a protein involved in immune evasion and shows sufficient genetic variability for differentiation from CAdV-2 [11, 18, 23]. Nested PCR, which involves two successive amplification rounds, offers even greater sensitivity, enabling the detection of inapparent infections in wildlife reservoirs. For instance, a study on UK red foxes found that 18.8% of animals with no gross or microscopic evidence of ICH were positive for CAdV-1 by nested PCR, highlighting the virus's ability to persist subclinically [25]. The versatility of PCR is further demonstrated by its application to non-invasive samples such as urine, which has been used to confirm active infection and viral shedding in clinical cases [3, 25]. In one case, PCR and subsequent sequence analysis of CAdV-1 from urine confirmed the diagnosis in a puppy with severe coagulation disorders [3].

Quantitative Real-Time PCR (qPCR): qPCR offers significant advantages over conventional PCR by providing not only qualitative detection but also quantification of the viral load. This is particularly valuable for assessing the severity of infection, monitoring response to therapy, and conducting epidemiological studies. Several qPCR assays have been developed and validated for CAdV-1. A SYBR Green-based real-time PCR assay with melting curve analysis has been optimized to simultaneously detect and differentiate CAdV-1 from CAdV-2, a critical capability given their shared biological matrices and potential for co-infection [44]. This assay exploits the differences in the melting temperature (Tm) of the amplified products, allowing for rapid and cost-effective serotype discrimination without the need for sequencing [44]. More advanced probe-based qPCR assays, such as those using a TaqMan probe targeting the orf 16 gene, have been developed for the indirect determination of viral infectivity titers in vaccine production, demonstrating a high correlation between the quantification cycle (Cq) and the 50% tissue culture infective dose (TCID50) [41]. This approach reduces analysis time to three hours and achieves a sensitivity of at least 1.0 lg TCID50/cm³ [41]. In epidemiological surveys, qPCR has been instrumental in detecting CAdV-1 in wildlife. For example, a study on free-ranging wolves in Spain used real-time PCR on spleen samples to reveal a 14% prevalence of CAdV-1 DNA, identifying young animals as the primary viral reservoir [14]. Similarly, qPCR has been used to confirm CAdV-1 in paraffin-embedded liver samples from European brown bears, providing retrospective evidence of the virus's role in mortality in this endangered species [16].

Multiplex PCR Panels: Given the high frequency of co-infections in canine infectious diseases, multiplex PCR panels that simultaneously detect CAdV-1 alongside other pathogens are invaluable. A comprehensive study on canine viral diseases in China utilized a multiplex approach to test for ten different pathogens, including CAdV-1, in a large sample set, revealing complex epidemiological patterns [12]. While many multiplex panels focus on the canine infectious respiratory disease complex (CIRDC) and include CAdV-2, the inclusion of CAdV-1 is less common in these panels but is critical for a complete diagnostic workup in cases of systemic or hepatic disease [20, 21, 29]. The development of a four-plex qPCR/RT-qPCR panel for CIRDC pathogens, for instance, included CAdV-2 but not CAdV-1, underscoring a potential diagnostic gap that should be addressed in clinical settings where ICH is a differential [20].

Serological Assays: ELISA and Virus Neutralization

Serological assays are essential for determining prior exposure, monitoring vaccine responses, and conducting large-scale serosurveillance studies. The two primary serological methods for CAdV-1 are the enzyme-linked immunosorbent assay (ELISA) and the virus neutralization (VN) test.

Enzyme-Linked Immunosorbent Assay (ELISA): The indirect ELISA (I-ELISA) is a high-throughput, cost-effective method for detecting anti-CAdV-1 antibodies. A well-characterized I-ELISA using column chromatography-purified CAdV-1 antigen has been developed and validated against the VN test, demonstrating a high sensitivity (97.0%) and a moderate specificity (74.2%), with an overall accuracy of 92.7% [19]. The correlation between I-ELISA and VN titers was found to be significant (r = 0.88), making it a suitable tool for large-scale serosurveys [19]. This assay is particularly useful for assessing herd immunity and identifying susceptible populations. For instance, a serological survey in the UK using ELISA estimated that 64.4% of red foxes were seropositive for canine adenovirus, indicating widespread exposure [25]. Similarly, a study in Turkey found a 54.7% seroprevalence of CAV antibodies in dogs using ELISA, confirming the high circulation of the virus [36]. However, a key limitation of standard ELISAs is their inability to differentiate between antibodies induced by CAdV-1 and CAdV-2 due to antigenic cross-reactivity. This is a critical consideration, as the widespread use of CAdV-2-based vaccines can lead to false-positive results for CAdV-1 exposure.

Virus Neutralization (VN) Test: The VN test is considered the gold standard for serological diagnosis due to its high specificity and ability to measure functional, protective antibodies. The test involves incubating serial dilutions of serum with a fixed amount of infectious CAdV-1, followed by inoculation of susceptible cells (e.g., MDCK cells). The highest serum dilution that completely inhibits the cytopathic effect (CPE) is recorded as the VN titer [19]. A titer of ≥1:2 is generally considered positive [19]. While highly specific, the VN test is labor-intensive, time-consuming (requiring up to 5 days), and requires cell culture facilities, making it less suitable for high-throughput screening compared to ELISA. Nevertheless, it remains the reference method for validating other serological assays and for assessing protective immunity in individual animals, particularly in the context of vaccine efficacy studies [17, 19, 43].

Virus Isolation and Immunohistochemistry

Virus Isolation: The isolation of CAdV-1 in cell culture provides definitive proof of the presence of infectious virus. The virus is typically propagated in Madin-Darby Canine Kidney (MDCK) cells, where it produces a characteristic cytopathic effect (CPE) within 3-5 days post-inoculation, including cell rounding, detachment, and the formation of grape-like clusters [26, 33, 35, 37]. The identity of the isolated virus can be confirmed by immunofluorescence assay (IFA) using specific anti-CAdV-1 antibodies or by electron microscopy, which reveals the characteristic icosahedral adenovirus particles [35, 42]. While virus isolation is a powerful tool for obtaining live virus for further characterization, such as whole-genome sequencing and phylogenetic analysis, it is less sensitive than PCR and is not routinely used for primary diagnosis due to its time-consuming nature and requirement for specialized laboratory infrastructure [26, 27, 31].

Immunohistochemistry (IHC): IHC is an invaluable technique for visualizing viral antigen directly within tissue sections, providing a direct link between the presence of the virus and the observed histopathological lesions. Using antibodies specific to CAdV-1, IHC can detect viral antigen in formalin-fixed, paraffin-embedded tissues, making it ideal for retrospective studies and archival samples [1, 7, 16, 40]. In cases of ICH, IHC consistently labels viral antigen within the nuclei and cytoplasm of hepatocytes, Kupffer cells, and vascular endothelial cells [1, 16]. This technique has been crucial in confirming CAdV-1 as the cause of death in a range of species, including brown bears, wolves, and foxes [7, 16, 22]. IHC is particularly useful in cases where histopathology is suggestive but not definitive, or when molecular testing is unavailable. For example, in a case of a puppy with neurological signs, IHC on brain tissue was essential for confirming CAdV-1 infection, as the histopathological findings of vasculitis and INIBs were not pathognomonic [22]. The technique also allows for the differentiation of CAdV-1 from other viral infections that may cause similar lesions, such as canine distemper virus [40].

Differential Diagnosis and Diagnostic Algorithm

The clinical and pathological presentation of ICH can overlap with other diseases, necessitating a systematic diagnostic approach. Key differential diagnoses include canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), leptospirosis, babesiosis, and toxic hepatopathies [11, 40]. Co-infections are common, further complicating the diagnosis. A study in India found that among dogs with clinical hepatitis, only 2.5% were positive for CAdV-1, while 20% had leptospirosis and 22.5% had babesiosis, highlighting the need for a broad diagnostic workup [11]. Similarly, retrospective IHC studies have revealed high rates of concomitant infections with CDV, CPV-2, and CAdV-1 in puppies that died suddenly [40].

A rational diagnostic algorithm should begin with a thorough clinical and epidemiological assessment, including vaccination history, age, and potential exposure to wildlife. In live animals, the collection of blood for hematology, serum biochemistry (noting elevated liver enzymes, hypoalbuminemia, and bilirubinemia), and coagulation profiles can provide strong supportive evidence [3, 5, 11, 15]. For definitive antemortem diagnosis, PCR on whole blood, urine, or conjunctival swabs is the method of choice due to its high sensitivity and rapid turnaround time [3, 8]. In deceased animals, a complete necropsy with histopathological examination is the first step. If characteristic INIBs and necrohemorrhagic hepatitis are observed, confirmatory testing via PCR on fresh or frozen liver tissue or IHC on formalin-fixed tissue is recommended. The use of a multiplex PCR panel that includes CAdV-1, CDV, and CPV-2 is highly advisable to rule out common co-infections. For serosurveillance, ELISA is the preferred initial screening tool, with VN testing used for confirmation in critical cases or when vaccine-induced immunity needs to be distinguished from natural infection. The adoption of a SYBR Green-based qPCR with melting curve analysis offers a particularly efficient and economical approach for both detection and serotype differentiation in a single assay [44]. By integrating these diverse diagnostic approaches, clinicians and researchers can achieve a comprehensive understanding of CAdV-1 infection, from individual case management to large-scale epidemiological monitoring, which is essential for the conservation of both domestic dogs and vulnerable wild canid populations.

Epidemiological Patterns and Host Range of Canine Adenovirus 1

Host Species Susceptibility and the Expanding Host Range

Canine adenovirus type 1 (CAdV-1) exhibits a remarkably broad host range that extends well beyond the domestic dog (Canis lupus familiaris), establishing it as a multi-host pathogen of significant ecological and conservation concern. While the domestic dog serves as the primary reservoir and the most clinically documented host, the virus has been identified across a diverse array of wild canids and, notably, multiple non-canid species, challenging traditional assumptions about host restriction.

Domestic Dogs and the Role of Vaccination Status. Among domestic dog populations, CAdV-1 infection is most frequently documented in unvaccinated or inadequately vaccinated individuals, particularly those under one year of age [2, 12, 37, 38]. The virus produces a spectrum of clinical outcomes ranging from subclinical infection to peracute fatal hepatitis, with mortality rates highest in puppies and juvenile animals. A comprehensive multi-year surveillance study in China (2018–2024) involving 2,492 samples from dogs across 22 provinces found an overall CAV-1 prevalence of 2.1%, with the virus detected sporadically and not strongly associated with vaccination status, though serological protection rates in vaccinated dogs reached 84.4% [12]. This pattern suggests that while vaccination effectively reduces clinical disease, ongoing low-level circulation persists even in populations with moderate vaccine coverage. In southern Italy, a study of 291 dogs with suspected gastrointestinal disease detected CAdV-1 in 2.1% of animals, exclusively among stray dogs (6 of 291), underscoring the vulnerability of free-roaming and shelter populations where vaccination is inconsistent [26]. Similarly, outbreaks in Italian shelters between 2001 and 2006 demonstrated that CAdV-1 continues to circulate even in regions with historical vaccination programs [31].

Wild Canids as Natural Reservoirs and Shedders. The virus has been documented in a wide range of wild canid species, many of which serve as asymptomatic carriers capable of environmental dissemination. Red foxes (Vulpes vulpes) have emerged as particularly important reservoir hosts. A seminal study in the United Kingdom found that 64.4% of 469 free-ranging red foxes were seropositive for canine adenovirus by ELISA, with 18.8% of 154 foxes harboring CAdV-1 DNA in tissues despite showing no gross or histopathological lesions [25]. Crucially, CAdV-1 was detected in the urine of three foxes with inapparent infections, confirming that subclinically infected wild canids shed virus into the environment and can maintain transmission cycles independent of domestic dog populations [25]. A multicentric European study examining red foxes from the United Kingdom, Italy, and Germany detected CAdV-1 DNA in 22% (19/86) of kidney samples via PCR targeting the E3 gene [18]. Notably, none of these animals exhibited pathological changes or immunohistochemical positivity in the examined tissues, reinforcing the concept that red foxes act as efficient, clinically silent viral shedders [18].

Gray wolves (Canis lupus) represent another critical wild canid reservoir. Long-term surveillance of 303 wolves in the Northwest Territories, Canada, over a 13-year period revealed a CAdV-1 prevalence of approximately 1% [28]. A more detailed investigation of 149 free-ranging wolves in Asturias, Spain, detected CAdV-1 DNA in 14% (21/149) of animals by real-time PCR [14]. Age distribution in this wolf population was strikingly skewed: all but one of the 20 positive animals with estimable ages were younger than 2 years, and only one of 46 adults (>2 years) tested positive [14]. This age-related prevalence pattern strongly suggests that most wolves acquire infection early in life and subsequently clear the virus, with persistent infections being rare. Importantly, seropositivity remained high across age classes, indicating that prior exposure confers immunity but antibodies persist. These findings position wolves as significant sentinels for CAdV-1 circulation in ecosystems shared with other vulnerable species.

Other wild canid species have also been affected. An outbreak in four captive sub-adult Indian wolves (Canis lupus pallipes) resulted in rapid death of all animals within 24 hours of symptom onset, demonstrating that naïve populations with no prior exposure can experience catastrophic mortality [1]. Similarly, an outbreak in dhole pups (Cuon alpinus) at an Indian biological park resulted in four fatalities following a short clinical course, with necropsy findings including severe icterus, hepatomegaly, and widespread petechiation [5]. Maned wolves (Chrysocyon brachyurus) are also highly susceptible; two captive-born 3-month-old puppies died following infection, with histopathological confirmation of CAdV-1 through intranuclear inclusion bodies in the liver and kidneys [8].

Transmission to Ursids and Implications for Conservation. The most striking expansion of the CAdV-1 host range involves transmission to bear species, where the virus causes a fatal disease clinically and pathologically indistinguishable from infectious canine hepatitis in canids. A free-ranging brown bear cub (Ursus arctos horribilis) from Alaska, found dead in October 2015, yielded adenoviral hexon protein sequences with 100% identity to CAdV-1 [7]. In Europe, CAdV-1 has been identified as a significant mortality factor for the endangered Cantabrian brown bear population (Ursus arctos arctos). A retrospective study of 21 free-ranging Cantabrian brown bears necropsied between 1998 and 2018 identified three fatal cases of infectious canine hepatitis, with gross lesions including petechial hemorrhages, friable yellowish liver, and gallbladder thickening; immunohistochemistry confirmed viral antigen in hepatocytes and Kupffer cells in three animals, while an additional bear tested positive by IHC in a broader retrospective screening [16]. The epidemiological link to sympatric wolf populations is compelling: wolves in the same region showed a 14% prevalence of CAdV-1 DNA, with the highest prevalence in the western area of Asturias, coinciding temporally and spatially with the fatal bear cases [14]. Wolves likely shed the virus into the environment through urine and feces, and brown bears, which frequently scavenge wolf kills and share overlapping territories, become exposed [14, 16]. This cross-species transmission pathway highlights the role of wild canids as bridging hosts, facilitating viral spillover into vulnerable non-canid populations.

Other Incidental and Potential Host Species. Beyond canids and ursids, CAdV-1 has been detected or implicated in additional species. Concurrent infections with other pathogens have been documented; for instance, a retrospective study in puppies identified intralesional CAdV-1 antigens in 8 of 15 animals that died suddenly, all of which also harbored canine distemper virus, demonstrating frequent co-infections in high-density populations [40]. Experimental evidence suggests that CAdV-1 can infect human cells in vitro, though the significance for human health remains unclear; historical studies detected antibodies in veterinary workers, but contemporary data are lacking [13]. The virus has not been classified as a zoonotic concern by the World Organisation for Animal Health (WOAH) or the World Health Organization (WHO), and current evidence does not support natural transmission to humans under field conditions.

Geographic Distribution and Prevalence Variability

CAdV-1 exhibits a worldwide distribution, but its prevalence varies dramatically by geographic region, vaccination coverage, and the presence of wildlife reservoirs. Serological surveys consistently demonstrate higher exposure rates in free-roaming and shelter populations compared to well-vaccinated owned dogs. In Turkey, a serological investigation using ELISA found that 54.7% of 188 dogs were seropositive for CAV antibodies, though virus isolation from the same population was unsuccessful, suggesting widespread prior exposure but low-level active shedding [36]. In Sweden, where natural infection was considered essentially absent from the study population, 26.1% of nonvaccinated dogs under 12 months had maternal antibodies to CAV-1, reflecting passive immunity rather than active infection [17].

Regional outbreaks continue to occur, particularly where vaccination programs are inconsistent. Four outbreaks in Italy between 2001 and 2006, three in southern Italian shelters and one involving imported Hungarian puppies, demonstrated that CAdV-1 remains endemic in resource-limited settings [31]. In India, a prospective study of 40 dogs with clinical hepatitis in Kerala found only 2.5% (1/40) positive for CAV-1 by PCR, with leptospirosis and babesiosis accounting for the majority of hepatitis cases [11]. However, a much larger survey in northeast India detected CAdV-1 DNA in 17.30% (36/208) of canine parvovirus-positive fecal samples, indicating frequent co-infections and underscoring the importance of multi-pathogen screening [9]. In China, the 2018–2024 surveillance found a CAV-1 positive rate of 2.1% among all tested dogs, with no significant seasonal variation, though the study noted that co-infections with other enteric viruses were common [12].

The virus's ability to persist in the environment contributes to its geographic stability. CAdV-1 is resistant to environmental conditions, surviving several days at room temperature and months at 4°C [38]. This environmental resilience facilitates indirect transmission through contaminated fomites, bedding, and water sources, particularly in kennel and shelter environments where sanitation may be inadequate.

Age, Sex, and Physiological Risk Factors

Age is the most consistently identified risk factor for CAdV-1 infection. Across multiple studies, juvenile animals, particularly those between 2 and 12 months of age, are disproportionately affected. In the Spanish wolf population, 19 of 20 CAdV-1-positive animals were younger than 2 years, with only one adult testing positive [14]. In domestic dogs, cases are overwhelmingly reported in puppies and young adults. A fatal case in a 56-day-old Yorkshire Terrier puppy in Portugal highlights the vulnerability of very young animals, particularly those receiving inadequate colostral antibodies from unvaccinated dams [37]. Another case involved a 5-week-old Husky cross puppy that presented with neurological signs and was euthanized due to rapid deterioration [22]. The 4-month-old puppy imported from Bulgaria that survived after intensive treatment underscores that age alone does not determine outcome, but younger animals are more likely to develop severe disease [3].

Sex does not appear to be a significant risk factor. In the Indian wolf outbreak, both sexes were affected equally, and the Italian shelter outbreaks involved both male and female dogs without apparent bias [1, 26, 38]. The Spanish wolf study found similar prevalence between males and females [14].

Vaccination status is the most critical modifiable risk factor. Unvaccinated dogs, particularly those in shelters or breeding kennels with high population turnover, are at greatest risk. The case report from Portugal demonstrated that after a fatal index case in an unvaccinated puppy, clinically healthy dogs on the same premises were seropositive 14 months later, confirming that the virus can circulate silently even in apparently healthy populations [37]. Maternal antibody interference can also influence disease patterns; nonvaccinated puppies under 12 weeks of age may become infected as maternal antibodies wane before they receive their first vaccination [17].

Transmission Dynamics and Environmental Persistence

CAdV-1 is transmitted primarily through direct contact with infected animals and indirect contact with contaminated fomites. The virus is shed in all body secretions, including urine, feces, saliva, and nasal discharge, with urinary shedding being particularly important for environmental contamination [25]. The detection of CAdV-1 DNA in urine from three asymptomatically infected red foxes demonstrates that subclinically infected animals, particularly wild canids, can disseminate the virus widely without clinical signs [25].

The incubation period typically ranges from 4 to 9 days, after which viral shedding begins prior to the onset of clinical signs and continues for several weeks in recovering animals. Chronically infected dogs may shed virus intermittently for months, serving as persistent sources of infection. In the shelter environment, where population density is high and sanitation may be inconsistent, transmission can be explosive, leading to outbreaks with high morbidity and mortality [31].

The molecular mechanisms underlying viral pathogenesis and transmission have been further elucidated by recent studies. CAdV-1 infection induces PANoptosis, a programmed cell death pathway involving pyroptosis, apoptosis, and necroptosis, in canine splenocytes through activation of the AIM2 inflammasome [39]. This inflammatory response, particularly pronounced in immune organs like the spleen, tonsils, and lymph nodes, may contribute to viral dissemination by damaging the mucosal immune barrier and facilitating systemic spread. The virus's ability to induce cell death in T and B cells could also impair the host's ability to mount an effective adaptive immune response, prolonging the shedding period [39].

Molecular Epidemiology and Strain Diversity

Molecular characterization of CAdV-1 isolates from diverse geographic regions and host species reveals a complex epidemiological picture. The E3 gene, which encodes proteins involved in immune evasion, exhibits notable variability. Sequence analysis of Indian CAdV-1 isolates from northeast India revealed several amino acid mutations, including Asn127Asp, His129Arg, Trp148Ser, Leu201Pro, Thr206Met, and Gly215Glu, with distinct regional clustering consistent with local viral evolution [9]. A fatal case in an 18-month-old mixed breed dog revealed a N127D mutation in the E3 protein, previously reported only in one Indian sequence [15]. An Indian isolate from a Rajapalayam breed dog showed 99.78% nucleotide and 98.91% amino acid identity with a fox isolate from the United Kingdom, along with a unique W126S substitution in the E3 protein [2]. These findings suggest that Indian CAdV-1 strains are evolving independently but share ancestry with European isolates, likely reflecting historical introduction events followed by local adaptation.

In Italy, sequence analysis of CAdV-1 from six stray dogs revealed divergences from previously described Italian strains and closer relations with older international isolates, indicating genetic heterogeneity and ongoing evolution [26]. A whole-genome sequence of a CAdV-1 isolate from a free-ranging wolf in southern Italy further expanded the known genetic diversity of the virus [27]. Similarly, the F1301 strain isolated from a fox in China demonstrated 30,535 bp genome with high homology to other CAdV-1 strains, and transcriptomic analysis of infected MDCK cells revealed activation of PI3K-AKT, Wnt, and multiple viral infection pathways, confirming the virus's ability to reprogram host cellular machinery [33].

Selection pressure analysis of Indian isolates revealed predominantly purifying selection, with a few codons under weak or episodic positive selection, likely reflecting host immune adaptation [9]. No evidence of recombination was detected, suggesting that CAdV-1 evolves through point mutations rather than reassortment. The high amino acid homology (96–100%) among global strains indicates that despite geographic separation, CAdV-1 maintains a relatively conserved genome, which bodes well for the continued efficacy of existing vaccines [9].

The distinction between CAdV-1 and CAdV-2, while sometimes blurred in clinical settings, is critical for accurate epidemiological surveillance. CAdV-2 primarily causes respiratory disease and is frequently identified in dogs with canine infectious respiratory disease complex (CIRDC), where it may be detected in 2–4% of cases [20, 21, 29]. However, CAdV-2 has also been associated with neurological disease in vaccinated dogs, complicating clinical differentiation [42]. Molecular assays designed to distinguish the two serotypes, such as SYBR Green real-time PCR with melting curve analysis, are essential for accurate diagnosis and surveillance [44].

Therapeutic Strategies and Management of Infectious Canine Hepatitis

The management of infectious canine hepatitis (ICH) demands a multifaceted approach that integrates aggressive supportive care, meticulous monitoring for life-threatening complications, and a fundamental reliance on preventive vaccination as the cornerstone of population-level control. Given the acute and frequently peracute nature of the disease, particularly in naïve juvenile and wild canid populations, therapeutic intervention must be initiated emergently and tailored to the specific pathophysiological derangements induced by canine adenovirus type 1 (CAdV-1) infection. The clinical trajectory can be catastrophic, with death occurring within 24 to 48 hours of symptom onset in severe cases, as documented in outbreaks involving Indian wolves, maned wolf puppies, and dhole pups [1, 5, 8]. Consequently, a deep understanding of the underlying mechanisms, including direct viral cytopathic effects on hepatocytes and endothelial cells, immune-mediated destruction, and the induction of systemic coagulopathy, is essential for formulating a rational therapeutic plan.

Core Principles of Antiviral and Supportive Intervention

No specific, licensed antiviral drug is currently approved for the treatment of CAdV-1 infection in canids. Therapeutic efforts are therefore directed at sustaining organ function while the host’s immune system mounts a neutralizing antibody response. The virus induces a profound necrotizing hepatitis and widespread vasculitis, leading to a predictable cascade of complications: disseminated intravascular coagulation (DIC), hepatic failure with hypoalbuminaemia, and severe haemorrhagic tendencies [1, 3, 5]. The cornerstone of management is intensive supportive care, often requiring hospitalization, intravenous fluid therapy, and blood product transfusion.

A critical case report by Polovitzer et al. (2022) provides the most detailed roadmap for managing the coagulation disorders and hypoalbuminaemia that typify severe ICH [3]. In a 4-month-old mixed-breed puppy imported from Bulgaria, presenting with pyrexia, icterus, melaena, and bleeding from venipuncture sites, the therapeutic protocol involved a coordinated strategy: initial transfusion with whole blood and fresh frozen plasma (FFP) to address anaemia and replenish clotting factors, followed by repeated administration of human albumin to correct severe, life-threatening hypoalbuminaemia. The use of human albumin in veterinary medicine is controversial due to the risk of immune-mediated reactions, but in this case, it was deemed necessary to manage peripheral oedema of the head and limbs that developed during disease progression. The puppy was discharged on day eight [3]. This case underscores that aggressive, multi-modal supportive care can be successful even in the face of severe hepatic synthetic failure and coagulopathy. The peripheral oedema observed is a direct consequence of reduced oncotic pressure from hypoalbuminaemia, which is often exacerbated by increased vascular permeability from CAdV-1-induced endothelial damage [1, 8]. Therefore, monitoring of serum albumin, coagulation times (prothrombin time, activated partial thromboplastin time), and platelet counts is paramount. Thrombocytopaenia, frequently noted in acute cases, contributes significantly to the haemorrhagic diathesis [5, 11].

Management of Specific Clinical Complications

Haemostatic Derangements: The vascular endothelial cell is a primary target for CAdV-1 replication, leading to direct endothelial injury, exposure of subendothelial collagen, and activation of the coagulation cascade. This, combined with impaired hepatic synthesis of clotting factors and thrombocytopenia from platelet consumption and potential immune-mediated destruction, creates a high-risk scenario for DIC. The use of FFP is not merely supportive; it is therapeutic, providing a source of antithrombin III, fibrinogen, and factors II, VII, IX, and X. In cases where anaemia is significant, whole blood transfusion may be indicated. The decision to transfuse should be guided by serial haematocrit measurements and clinical evidence of ongoing haemorrhage (e.g., melaena, petechiae, ecchymoses) [3, 5].

Hepatic Encephalopathy and Metabolic Support: While less commonly reported, hepatic encephalopathy can occur in end-stage disease. Management includes lactulose administration to reduce intestinal ammonia absorption and dietary protein restriction. Hepatic protectants such as S-adenosylmethionine (SAMe) and silybin (milk thistle) are often employed empirically to support hepatocellular function and reduce oxidative stress, although their efficacy in acute viral hepatitis is not robustly proven. The oxidant-antioxidant imbalance observed in acute ICH, characterized by marked increases in serum oxidants and decreased antioxidant levels, provides a rationale for antioxidant therapy [15]. Intravenous fluids should be chosen carefully; balanced crystalloids (e.g., lactated Ringer's solution) are generally preferred, but in cases of severe hepatic dysfunction, consideration of fluids containing acetate or gluconate as a buffer may be prudent to avoid lactate accumulation.

Renal Involvement and "Blue Eye": CAdV-1 also exhibits tropism for renal tubular epithelium and the corneal endothelium. Acute interstitial nephritis and glomerular degeneration are noted histopathologically [8, 15]. Urine output should be monitored, and azotaemia managed with appropriate fluid therapy. The classic "blue eye" phenomenon, corneal oedema resulting from immune complex deposition in the endothelium, typically appears 7–14 days post-infection and is often self-limiting, but topical anti-inflammatory therapy (e.g., topical corticosteroids or non-steroidal anti-inflammatory drugs under veterinary guidance) may be indicated to reduce uveitis and corneal opacity. However, systemic immunosuppression is contraindicated during the active viral replication phase. It is critical to note that "blue eye" is primarily a post-vaccinal complication with older CAV-1 vaccines and is less common with natural infection, but remains a potential sequela [40].

Vaccination as the Definitive Management Strategy

The most effective "therapeutic" strategy for ICH is prevention. Widespread vaccination has dramatically reduced the incidence of clinical disease in regions with high coverage, but the disease persists in unvaccinated populations and wildlife reservoirs [6, 31]. The current gold standard is the use of modified-live vaccines (MLV) containing canine adenovirus type 2 (CAdV-2), which confers robust cross-protection against CAdV-1 without the risk of inducing post-vaccinal corneal oedema or other adverse effects associated with early CAV-1 vaccines [10, 24, 43]. Bass et al. (1980) demonstrated conclusively that a CAdV-2 MLV strain was safe, genetically stable, and immunogenic; it protected dogs against lethal CAV-1 challenge and did not cause ocular lesions, in contrast to a CAV-1 vaccine strain which induced such lesions in 21.6% of control dogs [10]. This strategic replacement of CAV-1 with CAV-2 in core vaccines represents one of the most significant advances in canine preventive medicine.

Vaccination is typically administered as part of a multivalent core vaccine (e.g., combined with canine distemper virus, canine parvovirus, and parainfluenza) starting at 6–8 weeks of age, with boosters every 3–4 weeks until 16 weeks of age, and a booster at one year. Serological studies indicate that protective antibody titers (≥1:16) are achieved in a high proportion of vaccinated dogs; in one Swedish study, 63.2% of dogs under 12 months achieved adequate CAV-1 titers [17]. In China, a serosurvey found protective rates of 84.4% for CAV-1 in vaccinated dogs [12]. However, the presence of maternally derived antibodies can interfere with vaccine take, particularly in pups under 12 weeks of age. The persistence of CAdV-1 in the environment is also a concern; the virus is resistant to lipid solvents and can survive for months at 4°C, necessitating rigorous disinfection protocols with sodium hypochlorite, formaldehyde, or glutaraldehyde in kennel environments [38].

Management of Outbreaks and Wildlife Implications

When ICH is diagnosed in a multi-dog household, kennel, or wildlife facility, immediate isolation of affected animals and strict quarantine of exposed animals are essential. Because CAdV-1 is shed in all body secretions, including urine for up to 6–9 months post-infection by recovered animals, environmental decontamination is challenging [25]. The virus can be detected in urine from inapparently infected red foxes, highlighting the role of wildlife as reservoirs for domestic dogs [25]. In captive settings like zoological parks or breeding facilities of endangered canids, prophylactic vaccination of all susceptible animals is critical. Fatal outbreaks have been documented in Indian wolves [1], dhole pups [5], and maned wolf puppies [8], demonstrating the devastating impact on conservation efforts. Vaccination of captive wild canids with MLV CAV-2 vaccines is generally considered safe and effective, but species-specific safety trials are rarely conducted. The emergence of CAdV-1 as a cause of mortality in free-ranging European brown bears (Ursus arctos arctos) in Spain further underscores the need for a One Health approach, where vaccination of domestic dogs in sympatric areas may serve to reduce spillover into vulnerable wildlife populations [14, 16].

Addressing Immunosuppression and Co-morbidities

The management of ICH is complicated by the high frequency of co-infections with other canine pathogens, including canine distemper virus, canine parvovirus, and Neospora caninum [9, 40]. Co-morbidities exacerbate the clinical course and complicate therapy. Furthermore, iatrogenic immunosuppression can precipitate severe disease. A recent study evaluating the JAK inhibitor ilunocitinib at three times the therapeutic dose found that treated dogs were more susceptible to a concurrent outbreak of ICH, with a treated dog succumbing to the virus [43]. This finding has direct clinical relevance: dogs receiving immunosuppressive therapies (e.g., corticosteroids, cyclosporine, JAK inhibitors) may be at increased risk for developing severe ICH upon exposure, and vaccination status should be carefully verified in such patients. The underlying mechanism may involve impaired CD4+ T helper cell counts and reduced cell-mediated immunity [43]. Thus, any dog presenting with acute hepatitis and a history of immunosuppressant use should be considered at high risk for atypical or fulminant ICH.

In summary, the management of infectious canine hepatitis demands a rapid, aggressive, and highly individualized approach centred on haemostatic support, correction of hypoalbuminaemia, and meticulous monitoring for multi-organ failure. While no specific antiviral exists, the availability of safe and highly effective cross-protective vaccines, specifically the CAV-2 modified-live vaccine, remains the most powerful tool for preventing this devastating disease. Clinicians must maintain a high index of suspicion for ICH in unvaccinated dogs and in regions where wildlife reservoirs maintain viral circulation. The re-emergence of this "old" disease in Europe [31] and its documented presence in diverse wild canids and ursids worldwide should prompt renewed vigilance and a commitment to core vaccination protocols.

Prevention and Control of Canine Adenovirus 1

Vaccination as the Cornerstone of Control

The prevention and control of infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAdV-1) rests fundamentally on comprehensive vaccination protocols, which have transformed this once-devastating disease into a largely preventable condition in regions with high vaccine coverage. The inclusion of CAdV-1 as a core vaccine component, as recommended by the World Organisation for Animal Health (WOAH) and major veterinary medical associations globally, reflects the virus's capacity to cause severe systemic disease and its propagation across both domestic and wild canid populations. Historically, the earliest vaccines utilized modified-live CAdV-1 strains; however, these formulations were associated with a notable adverse effect, the development of post-vaccinal corneal edema, colloquially termed "blue eye," observed in a significant proportion of recipients [10, 40]. This complication arises from the deposition of virus-antibody immune complexes within the corneal endothelium, triggering an inflammatory cascade that results in transient or, in rare cases, persistent corneal opacity. The recognition of this vaccine-induced pathology catalyzed a paradigm shift in immunization strategy, leading to the adoption of modified-live canine adenovirus type 2 (CAdV-2) vaccines as a safer yet equally efficacious alternative for protection against CAdV-1 [10, 24].

The immunological basis for this cross-protection is rooted in the significant antigenic homology between the two serotypes. CAdV-1 and CAdV-2 share approximately 70% genomic identity, and critical neutralizing epitopes present on the hexon and fiber proteins of CAdV-2 elicit antibodies that effectively neutralize CAdV-1 [24, 30]. Rigorous safety evaluations of CAdV-2 vaccine strains, including the prototype Toronto A26/61 strain, have demonstrated that these viruses are genetically stable, non-pathogenic even after serial back-passage in dogs, and do not induce the corneal lesions characteristic of CAdV-1 vaccines [10]. In one landmark study involving 37 dogs inoculated with a CAdV-1 vaccine strain, 21.6% developed post-vaccination ocular lesions, whereas 90 seronegative dogs receiving the CAdV-2 vaccine strain intravenously, a route chosen to maximize potential pathogenicity, remained entirely clinically normal [10]. Furthermore, immunogenicity trials have confirmed that CAdV-2-vaccinated dogs withstand lethal CAdV-1 challenge, exhibiting no clinical signs, and post-mortem examinations reveal no evidence of viral replication in tissues [10]. This cross-protective efficacy has been repeatedly validated in field conditions, where CAdV-2-based vaccines are now the gold standard for core vaccination programs in domestic dogs.

Despite the widespread availability of effective vaccines, significant gaps in population immunity persist, particularly in regions where vaccination is not mandatory, in stray animal populations, and in vulnerable wild canid communities. Serological surveys from varied geographical contexts underscore this challenge. In a comprehensive Chinese epidemiological study spanning 2018 to 2024 involving 2,492 dogs, the protective seroprevalence against CAdV-1 among vaccinated animals was 84.4%, indicating that while vaccines are highly effective, a substantial minority of vaccinated individuals may remain susceptible due to improper storage, administration, or host factors such as maternal antibody interference [12]. In Sweden, a country considered free from natural CAdV-1 circulation, 26.1% of non-vaccinated puppies younger than 12 months possessed maternally derived antibodies against CAdV-1 at titers ≥1:8, and 63.2% of vaccinated juveniles maintained protective titers [17]. The presence of maternal antibodies poses a well-recognized impediment to early immunization, as high titers can neutralize vaccine virus before the puppy's immune system mounts its own response. This phenomenon is less pronounced with modified-live CAdV vaccines compared to inactivated products, likely because the replicating vaccine virus can overcome low-to-moderate levels of passive immunity [17]. Current WOAH and veterinary consensus guidelines recommend initial core vaccination at 6–8 weeks of age, with boosters every 2–4 weeks until 16 weeks of age, followed by a booster at 6–12 months and revaccination every 1–3 years thereafter. The durability of vaccine-induced immunity is supported by studies showing that adult dogs maintain protective antibody titers for years following appropriate immunization [17].

Biosecurity, Hygiene, and Environmental Decontamination

While vaccination provides the primary defense, comprehensive prevention of CAdV-1 also demands rigorous biosecurity measures, particularly in high-risk environments such as kennels, shelters, breeding facilities, and wildlife rehabilitation centers. CAdV-1 is a non-enveloped adenovirus, a structural feature conferring exceptional environmental stability. The virus can persist for several days at room temperature and for months at temperatures ≤4°C, and it remains infectious in organic matter such as feces, urine, and contaminated fomites [38]. This resilience necessitates the use of appropriate disinfectants capable of inactivating non-enveloped viruses, including sodium hypochlorite (bleach) at a 1:32 dilution, chlorhexidine-based products, and accelerated hydrogen peroxide formulations. Quaternary ammonium compounds and phenolic disinfectants, while effective against many enveloped viruses, may be insufficient against CAdV-1 and should be verified through label claims.

Transmission occurs primarily through the fecal-oral route, direct contact with infected animals, or exposure to contaminated environments and fomites. Urine is a particularly important vector, as CAdV-1 is shed in high titers in the urine of both clinically ill and asymptomatically infected animals for extended periods, often for months after clinical recovery [25, 31]. This chronic shedding pattern, which can persist for up to 6–9 months following infection, means that apparently healthy recovered animals can serve as silent reservoirs, perpetuating viral circulation within a population. In shelter environments, where canine density is high and turnover is rapid, this poses a formidable control challenge. Strict isolation protocols for any animal presenting with clinical signs consistent with ICH, including pyrexia, depression, abdominal pain, vomiting, diarrhea, and subcutaneous edema, are essential. The incubation period is typically 4–9 days, and newly introduced animals should undergo a minimum 14-day quarantine period with rigorous monitoring before integration into the general population.

Control of outbreaks in kennels and shelters requires a multipronged approach: immediate isolation of affected animals, enhanced disinfection of all surfaces and equipment with virucidal agents, limitation of animal movement, and, critically, emergency vaccination of all in-contact animals irrespective of prior vaccination history. Modified-live CAdV-2 vaccines, when administered during an outbreak, can rapidly boost immunity and reduce viral shedding, a strategy supported by both experimental evidence and field observations [10]. In one notable outbreak series in Italian shelters, CAdV-1 was identified alongside canine distemper virus, canine parvovirus, and canine coronavirus, highlighting the frequency of polymicrobial infections in stressed, unvaccinated populations [31]. Such coinfections complicate diagnosis, worsen clinical outcomes, and demand that control measures address the entire pathogen complex rather than CAdV-1 alone.

Control in Wildlife Populations and at the Domestic-Wildlife Interface

The prevention of CAdV-1 in wildlife populations presents unique and formidable challenges, as vaccination campaigns are logistically and ethically complex in free-ranging animals. The virus has been documented in a remarkably broad range of hosts, including gray wolves (Canis lupus), red foxes (Vulpes vulpes), arctic foxes, dholes (Cuon alpinus), maned wolves (Chrysocyon brachyurus), and even ursids such as the European brown bear (Ursus arctos arctos) and the Alaskan brown bear (Ursus arctos horribilis) [1, 5, 7, 8, 14, 16, 18, 28]. The spillover of CAdV-1 from domestic dogs into wildlife populations is a well-established phenomenon, with profound implications for conservation of endangered species. In the Cantabrian Mountains of northern Spain, molecular surveillance has demonstrated that free-ranging wolves act as sentinels and reservoirs for CAdV-1, with a 14% prevalence of viral DNA in sampled wolves, and that fatal ICH has occurred in sympatric endangered brown bears [14, 16]. Phylogenetic analyses of CAdV-1 isolates from wolves, bears, and domestic dogs in the same geographic region reveal high genetic identity, confirming cross-species transmission and the role of domestic canids as the likely source of infection for naïve wildlife populations [14, 16, 27].

Red foxes have emerged as particularly important wildlife reservoirs. In the United Kingdom, an extensive survey found that 64.4% of 469 free-ranging red foxes were seropositive for canine adenovirus, with 18.8% harboring CAdV-1 DNA in tissues including liver, kidney, spleen, brain, and lung, despite the absence of clinical disease at necropsy [25]. Critically, CAdV-1 was detected in the urine of three foxes with inapparent infections, confirming that these animals actively shed virus into the environment [25]. Similarly, a multicentric European study detected CAdV-1 DNA in 22% of kidney samples from red foxes in Italy, Germany, and the United Kingdom, with no associated pathology, reinforcing the concept of foxes as clinically silent shedders that may sustain viral circulation even in the absence of overt outbreaks [18]. These findings have direct consequences for captive wildlife management: facilities housing endangered canids or susceptible non-canid species such as bears must enforce stringent biosecurity protocols, including vaccination of all domestic dogs on-site with CAdV-2 vaccines, exclusion of free-ranging canids, and disinfection of footwear and equipment.

The threat to captive wildlife was tragically illustrated by an outbreak in captive Indian wolves (Canis lupus pallipes), where four sub-adult animals died within 24 hours of symptom onset, with necropsy revealing characteristic hepatic necrosis, widespread hemorrhages, and basophilic intranuclear inclusion bodies confirmed as CAdV-1 by immunohistochemistry and PCR [1]. Similarly, an outbreak in dhole pups at an Indian biological park resulted in the death of four animals following a short clinical course characterized by icterus, hemorrhagic diathesis, and severe hepatic injury [5]. These episodes underscore the extreme susceptibility of naïve wildlife populations and the necessity of preventive vaccination for captive collections. While routine vaccination of wild canids in situ is not feasible, targeted oral bait vaccines have been explored for other carnivore pathogens (e.g., rabies) and represent a potential avenue for future research in CAdV-1 control, though no such product is currently licensed for adenoviruses.

Surveillance, Diagnostics, and Strategic Monitoring

Effective prevention and control are inextricably linked to robust surveillance systems capable of detecting CAdV-1 circulation before clinical outbreaks occur. Molecular diagnostics, particularly polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR), have revolutionized detection capabilities, enabling sensitive and specific identification of CAdV-1 DNA in a variety of clinical samples, including whole blood, urine, feces, and post-mortem tissues [41, 44]. A validated SYBR Green real-time PCR assay that differentiates CAdV-1 and CAdV-2 through melting curve analysis has proven highly effective for both clinical diagnosis and epidemiological surveillance, with the advantage of simultaneously detecting both serotypes in cases of coinfection [44]. This distinction is clinically important, as CAdV-2 primarily causes respiratory disease and does not carry the same systemic pathogenicity, yet the two viruses may cocirculate, particularly in shelter environments [44]. Quantitative PCR methods have also been developed to determine viral infectivity titers in vaccine production, linking the quantification cycle (Cq) to TCID50 values through a validated logarithmic function, which ensures consistency and potency of vaccine batches [41].

Serological surveillance using enzyme-linked immunosorbent assays (ELISA) provides complementary information regarding population-level immunity and historical exposure. An indirect ELISA employing column-chromatographically purified CAdV-1 antigen demonstrated 97.0% sensitivity and 74.2% specificity compared to the gold-standard virus neutralization test, with an overall accuracy of 92.7% and a strong correlation coefficient of 0.88 [19]. Such assays are invaluable for large-scale serosurveys to identify gaps in vaccine coverage and to monitor the effectiveness of control programs. In a canine population in Turkey, ELISA screening revealed that 54.7% of 188 dogs possessed antibodies against canine adenovirus, indicating widespread exposure even in the absence of clinical disease [36]. These data are essential for risk assessment and for guiding vaccination strategies in regions where ICH is considered re-emerging, as has been suggested by recent cases in Italy, Portugal, and India [2, 3, 26, 31, 37].

The importation of dogs from regions with low vaccination coverage poses a particular risk for the reintroduction of CAdV-1 into areas where the disease has become rare. A case report from Austria documented severe ICH in a 4-month-old puppy imported from Bulgaria, requiring intensive care including whole blood and fresh frozen plasma transfusions, as well as human albumin administration for life-threatening hypoalbuminemia [3]. This case, and others involving puppies imported from Hungary [31], highlights the need for pre-import vaccination requirements and quarantine protocols to prevent the re-establishment of CAdV-1 in populations that have been largely protected through sustained vaccination. The World Organisation for Animal Health (WOAH) recommends that international movement of dogs be accompanied by documentation of core vaccination, including adenovirus, and that importing countries maintain awareness of the epidemiological status of source regions. In wildlife contexts, the use of sentinel species, particularly wolves, which demonstrate high seroprevalence and are sympatric with domestic dogs and endangered species, can provide early warning of viral circulation and inform targeted interventions in high-risk areas [14].

References

[1] Karikalan M. Pathology of infectious canine hepatitis in captive Indian wolves (Canis lupus pallipes): An outbreak study. Indian Journal of Veterinary Pathology. 2025. DOI: https://doi.org/10.56093/vt5c1d20

[2] Syamily S, Rajasekhar R, Anoopraj R, Ravishankar C, Jishnu HP. Detection and molecular characterisation of canine adenovirus type 1 from a fatal case of infectious canine hepatitis from India. Veterinary Record Case Reports. 2023. DOI: https://doi.org/10.1002/vrc2.698

[3] Polovitzer J, Guija-de-Arespacochaga A, Auer A, Künzel F. Successful treatment of coagulation disorders and hypoalbuminaemia in a puppy with Infectious Canine Hepatitis.. Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere. 2022. DOI: https://doi.org/10.1055/a-1907-0877

[4] Wang C, Wang D, Yin G, Wang Y, Lu M, Zhang Z, et al.. Isolation and characterization of canine adenovirus type 2 (CAV-HN45) and its selective infection of human cervical cancer cells with preliminary oncolytic potential. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1692395

[5] Manjunatha V, Rout M, Srinivas U, Kshamaa LM, Sujay S, Sripad K, et al.. Fatal Canine Adenovirus Type 1 Infection in Dhole (Cuon alpinus) Pups. Indian Journal of Animal Research. 2024. DOI: https://doi.org/10.18805/ijar.b-5164

[6] Jonge BD, Brantegem LV, Chiers K. Infectious canine hepatitis, not only in the textbooks: a brief review and three case reports. Vlaams Diergeneeskundig Tijdschrift. 2020. DOI: https://doi.org/10.21825/vdt.v89i5.16956

[7] Knowles S, Bodenstein B, Hamon TR, Saxton MW, Hall JS. Infectious Canine Hepatitis in a Brown Bear (Ursus arctos horribilis) from Alaska, USA. Journal of Wildlife Diseases. 2018. DOI: https://doi.org/10.7589/2017-10-245

[8] Pereira FM, Oliveira ADd, Melo ES, Soares-Neto LL, Mangueira DK, Santos DOd, et al.. Naturally Acquired Infectious Canine Hepatitis in Two Captive Maned Wolf (Chrysocyon brachyurus) Puppies.. Journal of Comparative Pathology. 2021. DOI: https://doi.org/10.1016/j.jcpa.2021.05.006

[9] Behera S, Maibam L, Lalhmangaihzuali M, Sahu B, Sahu J, Marak AN, et al.. Genomic and immunoinformatic characterization of canine adenovirus type 1 in parvovirus-infected dogs: A comprehensive study from northeast India.. Polish journal of veterinary sciences. 2026. DOI: https://doi.org/10.24425/pjvs.2026.158511

[10] Bass E, Gill MA, Beckenhauer WH. Evaluation of a canine adenovirus type 2 strain as a replacement for infectious canine hepatitis vaccine.. Journal of the American Veterinary Medical Association. 1980. DOI: https://doi.org/10.2460/javma.1980.177.03.234

[11] Joseph A, Vinodkumar K, Tresamol P, Vijayakumar K, Sajitha I. Aetiopathology of canine hepatitis in Kerala. Journal of Veterinary and Animal Sciences. 2023. DOI: https://doi.org/10.51966/jvas.2023.54.2.477-485

[12] Liu C, Chen Y, Cui N, Yang Y, Ding H, Wu H, et al.. Molecular detection of canine viral infectious diseases in China: an investigation from 2018 to 2024. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2025.1709294

[13] Smith K, Gehle W, Kniker W. Serologic evidence that infectious canine hepatitis virus commonly infects humans and is related to human adenovirus type 8.. Journal of Immunology. 1970. DOI: https://doi.org/10.4049/jimmunol.105.4.1036

[14] Oleaga Á, Balseiro A, Espí A, Royo L. Wolf (Canis lupus) as canine adenovirus type 1 (CAdV-1) sentinel for the endangered Cantabrian brown bear (Ursus arctos arctos).. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14010

[15] Chakraborty P, Behera S, Arya R, Maibam L, Lalhriatchhungi MH. Genetic characterisation of canine adenovirus type 1 in an 18‐month‐old mixed breed male dog and its effect on clinico‐pathology, hemato‐biochemistry and serum oxidant–antioxidant status. Veterinary Record Case Reports. 2024. DOI: https://doi.org/10.1002/vrc2.842

[16] Marín JFG, Royo L, Oleaga Á, Gayo E, Alarcia O, Pinto D, et al.. Canine adenovirus type 1 (CAdV‐1) in free‐ranging European brown bear (Ursus arctos arctos): A threat for Cantabrian population?. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.13013

[17] Olson P, Klingeborn B, Hedhammar Å. Serum antibody response to canine parvovirus, canine adenovirus-1, and canine distemper virus in dogs with known status of immunization: study of dogs in Sweden.. American Journal of Veterinary Research. 1988. DOI: https://doi.org/10.2460/ajvr.1988.49.09.1460

[18] Verin R, Forzan M, Schulze C, Rocchigiani G, Balboni A, Poli A, et al.. Multicentric Molecular and Pathologic Study On Canine Adenovirus Type 1 in Red Foxes (Vulpes vulpes) in Three European Countries.. Journal of Wildlife Diseases. 2019. DOI: https://doi.org/10.7589/2018-12-295

[19] Yang D, Kim H, Lee S, Ji M, Han B, Oh S, et al.. Development of an Indirect ELISA Featuring Plates Coated with Column Chromatographically Purified Canine Adenovirus Type-1 Antigen. Journal of Bacteriology and Virology. 2020. DOI: https://doi.org/10.4167/jbv.2020.50.1.017

[20] Thieulent CJ, Carossino M, Peak L, Strother K, Wolfson W, Balasuriya UBR. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. DOI: https://doi.org/10.3390/v15091881

[21] Yondo A, Kalantari A, Fernandez-Marrero I, McKinney A, Naikare HK, Velayudhan B. Predominance of Canine Parainfluenza Virus and Mycoplasma in Canine Infectious Respiratory Disease Complex in Dogs. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12111356

[22] Hornsey SJ, Philibert H, Godson D, Snead ECR. Canine adenovirus type 1 causing neurological signs in a 5-week-old puppy. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-2173-5

[23] Timurkan M, Aydın H, Alkan F. Detection and molecular characterization of canine adenovirus type 2 (CAV-2) in dogs with respiratory tract symptoms in shelters in Turkey. Veterinarski arhiv (Tisak). 2018. DOI: https://doi.org/10.24099/VET.ARHIV.0052

[24] Zhu Y, Xu J, Lian S, Zhang R, Hou J, Wang M, et al.. Difference Analysis Between Canine Adenovirus Types 1 And 2. Frontiers in Cellular and Infection Microbiology. 2022. DOI: https://doi.org/10.3389/fcimb.2022.854876

[25] Walker D, Fee S, Hartley G, Learmount J, O'Hagan M, Meredith A, et al.. Serological and molecular epidemiology of canine adenovirus type 1 in red foxes (Vulpes vulpes) in the United Kingdom. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep36051

[26] Mira F, Puleio R, Schiró G, Condorelli L, Bella SD, Chiaramonte G, et al.. Study on the Canine Adenovirus Type 1 (CAdV-1) Infection in Domestic Dogs in Southern Italy. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11111254

[27] Pizzurro F, Marcacci M, Zaccaria G, Orsini M, Cito F, Rosamilia A, et al.. Genome Sequence of Canine Adenovirus Type 1 Isolated from a Wolf (Canis lupus) in Southern Italy. Genome Announcements. 2017. DOI: https://doi.org/10.1128/genomeA.00225-17

[28] Canuti M, Fry K, Cluff HD, Mira F, Fenton H, Lang A. Co-circulation of five species of dog parvoviruses and canine adenovirus type 1 among gray wolves (Canis lupus) in northern Canada.. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14474

[29] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. DOI: https://doi.org/10.1016/j.mex.2023.102476

[30] Swango LJ, Wooding W, Binn L. A comparison of the pathogenesis and antigenicity of infectious canine hepatitis virus and the A26-61 virus strain (Toronto).. Journal of the American Veterinary Medical Association. 1970. DOI: https://doi.org/10.2460/javma.1970.156.12.1687

[31] Decaro N, Campolo M, Elia G, Buonavoglia D, Colaianni ML, Lorusso A, et al.. Infectious canine hepatitis: An “old” disease reemerging in Italy. Research in Veterinary Science. 2007. DOI: https://doi.org/10.1016/j.rvsc.2006.11.009

[32] Kim Y, Lee S, Kim Y, Na E, Park J, Oem J. Genetic Characteristics of Canine Adenovirus Type 2 Detected in Wild Raccoon Dogs (Nyctereutes procyonoides) in Korea (2017–2020). Veterinary Sciences. 2022. DOI: https://doi.org/10.3390/vetsci9110591

[33] Zhu Y, Sun J, Yan M, Lian S, Hu B, Lv S, et al.. The biological characteristics of the canine adenovirus type 1 from fox and the transcriptome analysis of the infected MDCK cell. Cell Biology International. 2020. DOI: https://doi.org/10.1002/cbin.11537

[34] Ji J, Li W, Hu W, Xu X, Kan Y, Yao L, et al.. Novel Genotype Definition and the First Epidemiological Investigation of Canine Adenovirus Type 2 in Dogs in Central China. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00534

[35] Yang D, Kim H, Lee E, Yoo J, Yoon S, Park J, et al.. Recharacterization of the Canine Adenovirus Type 1 Vaccine Strain based on the Biological and Molecular Properties. Journal of Bacteriology and Virology. 2019. DOI: https://doi.org/10.4167/jbv.2019.49.3.124

[36] Bulut O, Yapıcı O, Avci O, Şimşek A, Atlı K, Dik I, et al.. The Serological and Virological Investigation of Canine Adenovirus Infection on the Dogs. TheScientificWorldJournal. 2013. DOI: https://doi.org/10.1155/2013/587024

[37] Duarte M, Henriques AM, Lima C, Ochoa C, Mendes F, Monteiro M, et al.. Fatal canine adenovirus type 1 acute infection in a Yorkshire Terrier puppy in Portugal: a case report. Veterinarni Medicina. 2018. DOI: https://doi.org/10.17221/7482-VETMED

[38] Pradnyandika IPKA, Aliyya RFDA, Dina PA, Febrianty N, Wardana R, Darmayanti MD, et al.. Kajian Pustaka: Gambaran Klinis Infeksi Radang Hati Menular (Infectious Canine Hepatitis) pada Anjing. Indonesia Medicus Veterinus. 2022. DOI: https://doi.org/10.19087/imv.2022.11.4.649

[39] Li Y, Zhao Y, Wang W, Qi B, Lv Y, Wang S, et al.. Canine adenovirus type 1 induces PANoptosis in canine splenocytes via AIM2 inflammasome activation.. Veterinary Microbiology. 2026. DOI: https://doi.org/10.1016/j.vetmic.2026.110965

[40] Headley SA, Oliveira TE, Pereira AHT, Moreira JR, Michelazzo MZ, Pires BG, et al.. Canine morbillivirus (canine distemper virus) with concomitant canine adenovirus, canine parvovirus-2, and Neospora caninum in puppies: a retrospective immunohistochemical study. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-31540-0

[41] Doronin MI, Mikhalishin DV, Shishkova AA, Galkina TS, Shishkov A, Malygin MP. Quantitative PCR to determine the titer of infectious activity of the canine hepatitis virus. E3S Web of Conferences. 2024. DOI: https://doi.org/10.1051/e3sconf/202448601011

[42] Chander V, Sharma G, Bhatt M, Nandi S, Mahajan S, Singh M, et al.. Isolation and genetic characterization of canine adenovirus type 2 from a domestic dog showing neurological symptoms. Brazilian Journal of Microbiology. 2021. DOI: https://doi.org/10.1007/s42770-021-00540-0

[43] Fent GM, Despa S, Gabor L, Earll M, McCandless EE, O’Kelley S, et al.. Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™). BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04896-5

[44] Balboni A, Dondi F, Prosperi S, Battilani M. Development of a SYBR Green real-time PCR assay with melting curve analysis for simultaneous detection and differentiation of canine adenovirus type 1 and type 2.. Journal of Virological Methods. 2015. DOI: https://doi.org/10.1016/j.jviromet.2015.05.009